Black Diamond Therapeutics (NASDAQ: BDTX) made its public debut Thursday morning, opening at $33 after being priced at $19 per share.
The company listed its shares on the Nasdaq under the ticker symbol "BDTX."
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule and tumor-agnostic therapies.
JPMorgan, Jefferies, and Cowen and company are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering.